Cargando…

Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect

Status asthmaticus is a life-threatening condition with a high mortality rate of up to 10.3% [1]. Milger et al. recently described a rapid clinical improvement and a reduction in serum IgE levels in a patient with status asthmaticus who received salvage therapy with omalizumab [2]. This treatment is...

Descripción completa

Detalles Bibliográficos
Autores principales: Slevogt, Hortense, Brauer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889270/
https://www.ncbi.nlm.nih.gov/pubmed/35251928
http://dx.doi.org/10.1016/j.rmcr.2022.101614
_version_ 1784661359062941696
author Slevogt, Hortense
Brauer, Martin
author_facet Slevogt, Hortense
Brauer, Martin
author_sort Slevogt, Hortense
collection PubMed
description Status asthmaticus is a life-threatening condition with a high mortality rate of up to 10.3% [1]. Milger et al. recently described a rapid clinical improvement and a reduction in serum IgE levels in a patient with status asthmaticus who received salvage therapy with omalizumab [2]. This treatment is not approved for status asthmaticus. Therefore, the authors based their dose finding on the recommendations approved by the by the European Medicines Agency for the treatment of severe persistent allergic asthma. For this indication the maximum dose generally does not include an option for patients with a higher body weight and high IgE levels [2]. A significant number of patients with persistent severe allergic asthma cannot be treated because there are insufficient data to support the administration of omalizumab above the recommended maximum dose of 600mg every 2 weeks [3]. In contrast, there is a lot of evidence in the existing literature for a very good safety profile for omalizumab [4,5]. OBJECTIVE: Here we report for the first time the successful treatment of a patient with refractory status asthmaticus by salvage therapy with updosed omalizumab adjusted for actual baseline IgE level, body weight and effect.
format Online
Article
Text
id pubmed-8889270
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88892702022-03-03 Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect Slevogt, Hortense Brauer, Martin Respir Med Case Rep Case Report Status asthmaticus is a life-threatening condition with a high mortality rate of up to 10.3% [1]. Milger et al. recently described a rapid clinical improvement and a reduction in serum IgE levels in a patient with status asthmaticus who received salvage therapy with omalizumab [2]. This treatment is not approved for status asthmaticus. Therefore, the authors based their dose finding on the recommendations approved by the by the European Medicines Agency for the treatment of severe persistent allergic asthma. For this indication the maximum dose generally does not include an option for patients with a higher body weight and high IgE levels [2]. A significant number of patients with persistent severe allergic asthma cannot be treated because there are insufficient data to support the administration of omalizumab above the recommended maximum dose of 600mg every 2 weeks [3]. In contrast, there is a lot of evidence in the existing literature for a very good safety profile for omalizumab [4,5]. OBJECTIVE: Here we report for the first time the successful treatment of a patient with refractory status asthmaticus by salvage therapy with updosed omalizumab adjusted for actual baseline IgE level, body weight and effect. Elsevier 2022-02-22 /pmc/articles/PMC8889270/ /pubmed/35251928 http://dx.doi.org/10.1016/j.rmcr.2022.101614 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Slevogt, Hortense
Brauer, Martin
Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
title Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
title_full Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
title_fullStr Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
title_full_unstemmed Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
title_short Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
title_sort rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for ige level, body weight and effect
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889270/
https://www.ncbi.nlm.nih.gov/pubmed/35251928
http://dx.doi.org/10.1016/j.rmcr.2022.101614
work_keys_str_mv AT slevogthortense rescuetherapyforrefractorystatusasthmaticuswithupdosedomalizumabadjustedforigelevelbodyweightandeffect
AT brauermartin rescuetherapyforrefractorystatusasthmaticuswithupdosedomalizumabadjustedforigelevelbodyweightandeffect